Medicine guide

IMULDOSA IV

As listed in the register: IMULDOSA IV

5 mg · solution

  • Prescription only
  • Cancer treatments and immune-system medicines
Active substance
Ustekinumab
Made by
Accord Healthcare Inc

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

Medicine groupCancer treatments and immune-system medicinesL04AC05

Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet

How it works

From the US prescribing label for the same active substance (Stelara). It describes the substance, not this exact product.

Ustekinumab is a human IgG1қ monoclonal antibody that binds with specificity to the p40 protein subunit used by both the IL-12 and IL-23 cytokines.

IL-12 and IL-23 are naturally occurring cytokines that are involved in inflammatory and immune responses, such as natural killer cell activation and CD4+ T-cell differentiation and activation.

Peak level after13.5 days
Half-life80.2 days
Mostly cleared after≈ 57 weeksfive half-lives — our arithmetic
PeakHalf gone57 weeks0
The shape is a standard model drawn from the two times above, not a measurement. How fast a medicine acts and wears off also depends on the dose, the form and the person.

Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-09-08

Safety of the active substance

From the US prescribing label for the same active substance (Stelara). It describes the substance, not this exact product.

Must not be used by
  • STELARA is contraindicated in patients with clinically significant hypersensitivity to any ustekinumab product or to any of the excipients in STELARA [see Warnings and Precautions (5.5) ].
  • Clinically significant hypersensitivity to any ustekinumab product or to any of the excipients in STELARA.
Most common side effects

The most frequently observed malignancies other than non-melanoma skin cancer during the clinical trials were: prostate, melanoma, colorectal and breast.

Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

United StatesNo exact match for this strength and form

European UnionNo exact match for this strength and form

SpainNo exact match for this strength and form

NetherlandsNo exact match for this strength and form

SwitzerlandNo exact match for this strength and form

Details

Made byAccord Healthcare Inc
Active substanceUstekinumab
Used inCancer treatments and immune-system medicines
Strength5 mg
Formsolution
ClassificationL04AC05 · Cancer treatments and immune-system medicines
Routeintravenous
Dispensing (as stated by the register)SCHEDULE D · PRESCRIPTION
StatusApproved
MarketedNo — authorised but not currently marketed, according to the register
DIN02564882
DPD drug code106754

Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician

Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.